시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 바이러스 및 비바이러스 벡터 제조 시장 보고서(2025년)
Viral And Non-Viral Vector Manufacturing Global Market Report 2025
상품코드 : 1824472
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

바이러스 및 비바이러스 벡터 제조 시장 규모는 향후 수년간 비약적인 성장이 예상됩니다. 2029년에는 CAGR 21.0%로 성장할 전망이며, 220억 1,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 유전자 치료에 대한 수요 증가, 희소 질환 치료에 대한 용도 확대, 바이오제조 인프라에 대한 투자 증가, 정밀의료의 채용 확대 등에 기인하고 있습니다. 예측 기간 주요 동향은 차세대 바이러스 벡터 개발, 벡터 제조에서 CRISPR 및 cas9 기술의 사용 증가, 확장 가능하고 비용 효율적인 제조 공정에 대한 주력, 비바이러스 벡터 채택 증가, 세포 및 유전자 치료 제조 기술의 발전 등을 포함합니다.

향후 5년간의 성장률 21.0%라고 하는 예측은 전회 예측으로부터 0.1%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국 간 관세의 영향 때문입니다. 관세의 부과는 스위스와 네덜란드에서 수입되는 유전자 치료용 벡터 및 지질 나노입자 전달 시스템에 대한 접근을 제한하고, 최첨단 치료를 지연시키거나, 바이오 제조 비용을 증가시킬 수 있기 때문에 미국에 있어 심각한 과제가 될 수 있습니다. 또한 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 그 영향이 더욱 광범위해질 것으로 보입니다.

바이러스 및 비바이러스 벡터 제조 시장의 성장은 유전자 질환의 유병률 증가에 의해 촉진될 것으로 예측됩니다. 유전자 질환은 전형적인 DNA 서열의 편차로부터 발생합니다. 바이러스 벡터는 치료 유전자를 표적 세포에 전달하고 이러한 질환을 유발하는 결함 유전자를 다루는 데 중요한 역할을 합니다. 비바이러스성 벡터는 일반적으로 생체외 유전자 치료에 사용되며, 체외에서 세포를 변형시킨 후 환자에게 재도입합니다. 예를 들어, Versus Arthritis가 2023년 6월에 보고한 바와 같이, 류마티스 관절염, 건선성 관절염, 골관절염 환자 수가 증가할 것으로 예상되고, 유전성 질환의 발생률이 증가하고 있는 것으로 강조되어 바이러스 및 비바이러스 벡터 제조 시장의 성장을 가속하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Viral and non-viral vector manufacturing involves the production of viral and non-viral vectors, which are tools designed to deliver genetic material into cells. Viral vectors are employed in the treatment of human diseases and find applications in anticancer and gene therapies. On the other hand, non-viral vectors are utilized for various gene therapy applications, with a particular focus on vaccine development and the treatment of cancer.

The main types of viral and non-viral vectors in manufacturing are viral vectors and non-viral vectors. Viral vectors are commonly used in gene therapy and gene editing to introduce therapeutic genes or alter the expression of existing genes in living organisms. These vectors are applied in the treatment of various diseases, including cancer, genetic diseases, infectious diseases, cardiovascular diseases, and others. They play a crucial role in gene therapy, vaccinology, cell therapy, and other related fields.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The viral and non-viral vector manufacturing vectors market research report is one of a series of new reports from The Business Research Company that provides viral and non-viral vector manufacturing vectors market statistics, including viral and non-viral vector manufacturing vectors industry global market size, regional shares, competitors with a viral and non-viral vector manufacturing vectors market share, detailed viral and non-viral vector manufacturing vectors market segments, market trends and opportunities, and any further data you may need to thrive in the viral and non-viral vector manufacturing vectors industry. This viral and non-viral vector manufacturing vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral and non-viral vector manufacturing market size has grown rapidly in recent years. It will grow from $8.67 billion in 2024 to $10.28 billion in 2025 at a compound annual growth rate (CAGR) of 18.5%. The growth in the historic period can be attributed to the rising prevalence of genetic disorders, advancements in biotechnology, increasing investments in gene therapy research, growing awareness of personalized medicine, and regulatory support for gene therapy development.

The viral and non-viral vector manufacturing market size is expected to see exponential growth in the next few years. It will grow to $22.01 billion in 2029 at a compound annual growth rate (CAGR) of 21.0%. The growth in the forecast period can be attributed to rising demand for gene therapies, expanding applications in rare disease treatment, increasing investments in biomanufacturing infrastructure, and growing adoption of precision medicine. Major trends in the forecast period include the development of next-generation viral vectors, increased use of CRISPR or cas9 technology in vector manufacturing, focus on scalable and cost-effective manufacturing processes, rising adoption of non-viral vectors, and advancements in cell and gene therapy manufacturing technologies.

The forecast of 21.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to gene therapy vectors and lipid nanoparticle delivery systems imported from Switzerland and the Netherlands, potentially delaying cutting-edge treatments and increasing biomanufacturing costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the viral and non-viral vector manufacturing markets is anticipated to be fueled by the increasing prevalence of genetic disorders. Genetic disorders arise from deviations in the typical DNA sequence, and viral vectors play a crucial role in delivering therapeutic genes to target cells, addressing defective genes causing these disorders. Non-viral vectors are commonly employed in ex vivo gene therapy, modifying cells outside the body before reintroducing them into the patient. For example, as reported by Versus Arthritis in June 2023, the number of people with rheumatoid arthritis, psoriatic arthritis, and osteoarthritis is expected to rise, highlighting the escalating incidence of genetic disorders and thereby propelling the growth of viral and non-viral vector manufacturing markets.

The growth of the viral and non-viral vector manufacturing markets is expected to be driven by the increasing number of clinical trials. Clinical trials, essential for evaluating the safety and efficacy of medical interventions, rely on viral and non-viral vectors to deliver therapeutic genes and ensure vector quality throughout trial phases. According to data from ClinicalTrials.gov in December 2023, the number of registered clinical trials has risen, with an increase in both registration and completion figures, underlining the pivotal role of these vectors in supporting gene therapy clinical trials and contributing to market growth.

A prominent trend in the viral and non-viral vector manufacturing markets is technological advancements. Key companies are investing in advanced solutions to maintain their market position. For instance, in August 2022, Merck KGaA launched the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform, providing a comprehensive viral vector manufacturing package. This innovative platform enables biopharmaceutical companies to streamline process development, reducing time and costs associated with clinical manufacture, showcasing the significance of technological advancements in driving market growth.

Major companies in the viral and non-viral vector manufacturing market are actively pursuing partnerships to enhance profitability. Collaborative efforts involve biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), research institutions, and technology providers working together to improve efficiency, safety, and scalability of non-viral vector development and production. For instance, in September 2023, NecstGen and ProteoNic BioSciences collaborated to launch ProteoNic's 2G UNic premium vector technology, contributing to improved lentiviral (LV) vector development and production efficiency, ultimately benefiting gene therapies and non-vector processes.

In March 2023, Sartorius, a Germany-based supplier of pharmaceutical and laboratory equipment, acquired Polyplus for around $2.59 billion. This acquisition is intended to enhance Sartorius's position in the gene therapy and viral vector production markets by broadening its cell and gene therapy capabilities. Polyplus is a France-based biotechnology company specializing in the production of both viral and non-viral vectors for gene therapy applications.

Major companies operating in the viral and non-viral vector manufacturing market include Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.

North America was the largest region in the viral and non-viral vector manufacturing market in 2024. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the viral and non-viral vector manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The viral and non-viral vector manufacturing market includes revenues earned by entities by providing adeno-associated viral vectors, lentiviral vectors, retroviral vectors, adenoviral vectors, particle-based vectors, and chemical-based vectors. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Viral And Non-Viral Vector Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on viral and non-viral vector manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for viral and non-viral vector manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The viral and non-viral vector manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Viral And Non-Viral Vector Manufacturing Market Characteristics

3. Viral And Non-Viral Vector Manufacturing Market Trends And Strategies

4. Viral And Non-Viral Vector Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Viral And Non-Viral Vector Manufacturing Growth Analysis And Strategic Analysis Framework

6. Viral And Non-Viral Vector Manufacturing Market Segmentation

7. Viral And Non-Viral Vector Manufacturing Market Regional And Country Analysis

8. Asia-Pacific Viral And Non-Viral Vector Manufacturing Market

9. China Viral And Non-Viral Vector Manufacturing Market

10. India Viral And Non-Viral Vector Manufacturing Market

11. Japan Viral And Non-Viral Vector Manufacturing Market

12. Australia Viral And Non-Viral Vector Manufacturing Market

13. Indonesia Viral And Non-Viral Vector Manufacturing Market

14. South Korea Viral And Non-Viral Vector Manufacturing Market

15. Western Europe Viral And Non-Viral Vector Manufacturing Market

16. UK Viral And Non-Viral Vector Manufacturing Market

17. Germany Viral And Non-Viral Vector Manufacturing Market

18. France Viral And Non-Viral Vector Manufacturing Market

19. Italy Viral And Non-Viral Vector Manufacturing Market

20. Spain Viral And Non-Viral Vector Manufacturing Market

21. Eastern Europe Viral And Non-Viral Vector Manufacturing Market

22. Russia Viral And Non-Viral Vector Manufacturing Market

23. North America Viral And Non-Viral Vector Manufacturing Market

24. USA Viral And Non-Viral Vector Manufacturing Market

25. Canada Viral And Non-Viral Vector Manufacturing Market

26. South America Viral And Non-Viral Vector Manufacturing Market

27. Brazil Viral And Non-Viral Vector Manufacturing Market

28. Middle East Viral And Non-Viral Vector Manufacturing Market

29. Africa Viral And Non-Viral Vector Manufacturing Market

30. Viral And Non-Viral Vector Manufacturing Market Competitive Landscape And Company Profiles

31. Viral And Non-Viral Vector Manufacturing Market Other Major And Innovative Companies

32. Global Viral And Non-Viral Vector Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Viral And Non-Viral Vector Manufacturing Market

34. Recent Developments In The Viral And Non-Viral Vector Manufacturing Market

35. Viral And Non-Viral Vector Manufacturing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기